{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T06:10:13Z","timestamp":1780726213022,"version":"3.54.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","seizure-journal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.seizure.2023.09.011","type":"journal-article","created":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T01:19:57Z","timestamp":1694567997000},"page":"62-67","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9110-6403","authenticated-orcid":false,"given":"Kiyohito","family":"Terada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6487-2065","authenticated-orcid":false,"given":"Yuichi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Dimova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sami","family":"Elmoufti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Floricel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daya","family":"Chellun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7198-8621","authenticated-orcid":false,"given":"Terence J.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2023.09.011_bib0001","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1684\/epd.2020.1132","article-title":"Clinical, semiological, electroencephalographic, and neuropsychological features of \"pure\" neocortical temporal lobe epilepsy","volume":"22","author":"Maizuliana","year":"2020","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2023.09.011_bib0002","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1528-1157.1976.tb03409.x","article-title":"Differences between patients with temporal lobe seizures and those with other forms of epileptic attacks","volume":"17","author":"Rodin","year":"1976","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.09.011_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.seizure.2018.07.011","article-title":"Evaluation of long-term antiepileptic drug use in patients with temporal lobe epilepsy: assessment of risk factors for drug resistance and polypharmacy","volume":"61","author":"Bj\u00f8rke","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.09.011_bib0004","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.21037\/apm-20-1415","article-title":"Factors influencing the long-term prognosis of patients with temporal lobe epilepsy: a single center study","volume":"9","author":"Yang","year":"2020","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.seizure.2023.09.011_bib0005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2014.11.021","article-title":"Current understanding of the mechanism of action of the antiepileptic drug lacosamide","volume":"110","author":"Rogawski","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2023.09.011_bib0006","unstructured":"UCB Pharma. Vimpat\u00ae (lacosamide tablets, injection, oral solution) [US Prescribing Information], https:\/\/www.ucb.com\/sites\/default\/files\/2022-10\/VIMPAT_Current_COL_rev_09_2022.pdf; 2022 [accessed 1 May 2023]."},{"key":"10.1016\/j.seizure.2023.09.011_bib0007","unstructured":"UCB Pharma. Vimpat\u00ae (lacosamide) EMA Summary of Product Characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vimpat-epar-product-information_en.pdf; 2009 [last updated 2022] [accessed 1 May 2023]."},{"key":"10.1016\/j.seizure.2023.09.011_bib0008","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seizure.2023.09.011_bib0009","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.yebeh.2016.03.011","article-title":"Lacosamide in patients with temporal lobe epilepsy: an observational multicentric open-label study","volume":"58","author":"Borz\u00ec","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.09.011_bib0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","year":"1981","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.09.011_bib0011","series-title":"Clinical Neuroradiology: The ESNR Textbook","first-page":"891","article-title":"Temporal lobe epilepsy (TLE) and neuroimaging","author":"Alvarez-Linera","year":"2019"},{"key":"10.1016\/j.seizure.2023.09.011_bib0012","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123002431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123002431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T20:33:27Z","timestamp":1730493207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123002431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":12,"alternative-id":["S1059131123002431"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.09.011","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and tolerability of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed temporal lobe epilepsy: Post hoc analysis of a randomized, double-blind trial","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}